➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Moodys
Dow
Boehringer Ingelheim
Johnson and Johnson

Last Updated: May 14, 2021

DrugPatentWatch Database Preview

LUNESTA Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Lunesta patents expire, and when can generic versions of Lunesta launch?

Lunesta is a drug marketed by Sunovion Pharms Inc and is included in one NDA.

The generic ingredient in LUNESTA is eszopiclone. There are twenty drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the eszopiclone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lunesta

A generic version of LUNESTA was approved as eszopiclone by TEVA on May 23rd, 2011.

  Get Started for $10

Drug patent expirations by year for LUNESTA
Drug Prices for LUNESTA

See drug prices for LUNESTA

Drug Sales Revenue Trends for LUNESTA

See drug sales revenues for LUNESTA

Recent Clinical Trials for LUNESTA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of California, San DiegoPhase 2
VA Office of Research and DevelopmentPhase 4
Beth Israel Deaconess Medical CenterN/A

See all LUNESTA clinical trials

Paragraph IV (Patent) Challenges for LUNESTA
Tradename Dosage Ingredient NDA Submissiondate
LUNESTA TABLET;ORAL eszopiclone 021476 2008-12-15

US Patents and Regulatory Information for LUNESTA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-001 Dec 15, 2004 AB RX Yes No   Get Started for $10   Get Started for $10   Get Started for $10
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-002 Dec 15, 2004 AB RX Yes No   Get Started for $10   Get Started for $10   Get Started for $10
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-003 Dec 15, 2004 AB RX Yes Yes   Get Started for $10   Get Started for $10   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LUNESTA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-002 Dec 15, 2004   Get Started for $10   Get Started for $10
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-001 Dec 15, 2004   Get Started for $10   Get Started for $10
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-001 Dec 15, 2004   Get Started for $10   Get Started for $10
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-003 Dec 15, 2004   Get Started for $10   Get Started for $10
Sunovion Pharms Inc LUNESTA eszopiclone TABLET;ORAL 021476-003 Dec 15, 2004   Get Started for $10   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
AstraZeneca
Colorcon
Baxter
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.